The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma. The Swiss drug maker earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug used to treat patients less than two years old with spinal muscular atrophy. Novartis said that it had received nine reports overall of tumours in patients...
US regulator investigates tumour risk in children given Novartis gene therapy
SC
SCMP - Feed 91By Reuters
EXECUTIVE SUMMARY
The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma. The Swiss drug maker earlier in the day disclosed two cases in which tumours in children showed evidence of being linked to its gene therapy drug used to treat patients less than two years old with spinal muscular atrophy. Novartis said that it had received nine reports overall of tumours in patients...
Key Takeaways
- US regulator investigates tumour risk in children given Novartis gene therapy.
- The US Food and Drug Administration said on Friday it was investigating a risk of neoplasia, or tumour formation including malignancy, associated with Novartis’ gene therapy Zolgensma.
- Novartis said that it had received nine reports overall of tumours in patients...
Read Complete Original Article
Published originally on SCMP - Feed 91
